Abstract:Objectives: The study aimed to evaluate the effectiveness of aztreonam, aztreonam-avibactam, cefiderocol, and cefiderocol-avibactam against numerous New Delhi Metallo-β-Lactamase-producing E. coli isolates, and compare the in vitro activity of these antibiotics against ESBLs, AmpCs, and MBLs-producing isolates of E. coli . Materials and Methods: A total of 57 New Delhi metallo-β-lactamase-producing E.coli were analyzed. Broth microdilution testing was conducted for aztreonam, aztreonam-avibactam, cefiderocol, and cefiderocol-avibactam following the latest EUCAST guidelines. Minimum inhibitory concentrations were determined for each antibiotic using specific broth formulations and concentrations. Molecular typing through Multilocus Sequence Typing was performed to identify the molecular types. Results: Aztreonam-avibactam demonstrated superior in vitro activity compared to aztreonam, cefiderocol, and cefiderocol-avibactam against ESBLs, AmpCs, and metallo-β-Lactamase-producing E. coli isolates. Conclusion: Aztreonam-avibactam exhibited best efficacy against New Delhi Metallo-β-Lactamase-producing E. coli isolates that generate varied New Delhi Metallo-β-Lactamase compared to aztreonam, cefiderocol, and cefiderocol-avibactam. The study highlights the potential of aztreonam-avibactam in overcoming resistance mechanisms observed with other antibiotics, providing valuable insights into the treatment of infections due to New Delhi Metallo-β-Lactamase-producing E. coli strains. Further research is needed to explore the interaction between different resistance mechanisms and additional factors influencing antibiotic susceptibility. —Antibiotic resistance among Enterobacterales sp., is on the rise. Although all efforts to combat against multi-drug resistant Enterobacterales have been taken, treatment options have been limited. Therefore, a safe and efficient therapy is needed. In this regard, the study aimed to assess the effectiveness of aztreonam, aztreonam-avibactam, cefiderocol, and cefiderocol-avibactam against New Delhi Metallo-β-Lactamase producing E. coli , and to compare their in vitro activity against extended-spectrum β-lactamases (ESBL), AmpC β-lactamases, and metallo-β-lactamases (MBL)-producing E. coli isolates. A total of 57 NDM-producing E. coli isolates were tested using broth microdilution according to EUCAST guidelines. Minimum inhibitory concentrations were determined for each antibiotic. Molecular typing via Multilocus Sequence Typing was performed to identify molecular types. Results showed that aztreonam-avibactam exhibited superior in vitro activity compared to aztreonam, cefiderocol, and cefiderocol-avibactam against ESBLs, AmpCs, and MBLs-producing E. coli isolates. Aztreonam-avibactam demonstrated the best efficacy against NDM-producing E. coli isolates, suggesting its potential in overcoming resistance mechanisms observed with other antibiotics. This study provides valuable insights into the treatment of infections caused by NDM-producing strains and underscores the need for further research to elucidate interactions between different resistance mechanisms and additional factors influencing antibiotic susceptibility.

The growing threat of NDM-producing E. coli with penicillin-binding protein 3 mutations in the United States – is there a potential role for durlobactam?

Global Emergence of Escherichia Coli with PBP3 Insertions

I n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex

NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings

Complete Genomic Characterization of Two Escherichia Coli Lineages Responsible for a Cluster of Carbapenem-Resistant Infections in a Chinese Hospital

A new class of penicillin-binding protein inhibitors to address drug-resistant

A Natural Novel Mutation in the Bla NDM-5 Promoter Reducing Carbapenems Resistance in a Clinical Escherichia Coli Strain

Next generation antibiotic combinations to combat pan-drug resistant Klebsiella pneumoniae

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae

Tackling the unyielding: testing two novel approaches against NDM-producing Enterobacterales and Pseudomonas aeruginosa isolates collected in India

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline

Rapid Emergence of Resistance to Broad-Spectrum Direct Antimicrobial Activity of Avibactam

Resistance to Aztreonam-Avibactam Due to CTX-M-15 in the Presence of Penicillin-Binding Protein 3 with Extra Amino Acids in Escherichia Coli

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination Against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing Escherichia Coli and Klebsiella Pneumoniae

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales

Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions

The Effectiveness of Aztreonam, Aztreonam-Avibactam, Cefiderocol on blaNDM-Producing E. coli Isolates